We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
(+27%)
Cap. Flow
+$9.92M
Cap. Flow
% of AUM
0.69%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9
quarters
Top 10 Avg Time Held Equity + Options
4.7
quarters
Top 20 Avg Time Held Equity + Options
4.1
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.7
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXTM
NxStage Medical Inc.
NXTM
|
+$24.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$23.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$18.4M |
| 4 |
STJ
St Jude Medical
STJ
|
+$16.6M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 2 |
Humana
HUM
|
+$20.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$12.4M |
| 4 |
Baxter International
BAX
|
+$9.04M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.68% |
| 2 | Miscellaneous | 20.64% |
| 3 | Consumer Staples | 0.52% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SCMP
126
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $451K | 0.03% |
41,096
+40,337
| +5,314% | +$452K |
2015 Q3
3 quarters
|
|
127
Tenet Healthcare
THC
$21.5B
| $448K | 0.03% |
+16,200
| New | +$479K |
2016 Q2
0 quarters
|
|
128
Elevance Health
ELV
$92.2B
| $447K | 0.03% |
3,400
-347
| -9% | -$47.5K |
2016 Q1
1 quarter
|
|
|
ISEE
129
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $416K | 0.03% |
+8,145
| New | +$405K |
2016 Q2
0 quarters
|
|
130
DELISTED
Enzo Biochem, Inc.
ENZ
| $401K | 0.03% |
+67,113
| New | +$372K |
2016 Q2
0 quarters
|
|
131
SCYNEXIS
SCYX
$39.7M
| $380K | 0.03% |
2,188
| – | – |
2015 Q2
4 quarters
|
|
132
Stellantis
STLA
$12.9B
| $379K | 0.03% |
62,248
-311
| -0.5% | -$2.25K |
2015 Q2
4 quarters
|
|
133
Centene
CNC
$34B
| $353K | 0.02% |
9,896
| – | – |
2015 Q4
2 quarters
|
|
134
Grace Therapeutics
GRCE
$41.9M
| $336K | 0.02% |
4,928
| – | – |
2013 Q3
11 quarters
|
|
135
Intellia Therapeutics
NTLA
$1.67B
| $320K | 0.02% |
+15,000
| New | +$399K |
2016 Q2
0 quarters
|
|
136
Celldex Therapeutics
CLDX
$2.22B
| $312K | 0.02% |
+4,742
| New | +$301K |
2016 Q2
0 quarters
|
|
137
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $270K | 0.02% |
6,355
| – | – |
2015 Q4
2 quarters
|
|
138
Ferrari
RACE
$68.7B
| $254K | 0.02% |
6,200
| – | – |
2016 Q1
1 quarter
|
|
139
Novavax
NVAX
$2.11B
| $233K | 0.02% |
+1,600
| New | +$183K |
2016 Q2
0 quarters
|
|
140
Viatris
VTRS
$19.8B
| $216K | 0.02% |
+5,000
| New | +$221K |
2016 Q2
0 quarters
|
|
|
ONSIW
141
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
| $212K | 0.01% |
+462,500
| New | +$177K |
2016 Q2
0 quarters
|
|
|
ONSIZ
142
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
| $202K | 0.01% |
+462,500
| New | +$243K |
2016 Q2
0 quarters
|
|
143
DELISTED
Star Equity Holdings
STRR
| $129K | 0.01% |
500
| – | – |
2015 Q4
2 quarters
|
|
144
Abbott
ABT
$178B
| $120K | 0.01% |
+3,040
| New | +$121K |
2016 Q2
0 quarters
|
|
145
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $81K | 0.01% |
32,047
+28,571
| +822% | +$79.6K |
2016 Q1
1 quarter
|
|
146
DELISTED
Immunogen Inc
IMGN
| $79K | 0.01% |
+25,745
| New | +$161K |
2016 Q2
0 quarters
|
|
147
AbbVie
ABBV
$485B
| $77K | 0.01% |
+1,250
| New | +$76.2K |
2016 Q2
0 quarters
|
|
|
DPLO
148
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $76K | 0.01% |
+2,175
| New | +$68.4K |
2016 Q2
0 quarters
|
|
149
Herbalife
HLF
$1.49B
| $73K | 0.01% |
2,500
| – | – |
2016 Q1
1 quarter
|
|
|
ZLTQ
150
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $72K | 0.01% |
2,638
-119,362
| -98% | -$3.36M |
2016 Q1
1 quarter
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
- Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
- Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
- Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
- Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
- Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.
Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.